The aim of this study was to evaluate the efficacy of dexmedetomidine in combination with sufentanil or butorphanol for postoperative analgesia in patients undergoing laparoscopic resection of a gastrointestinal tumor.
Introduction
Sufentanil and butorphanol are often used for postoperative analgesia. Sufentanil alone is more likely to cause side effects and respiratory depression than when combined with 1 or more adjunctive drugs in intravenous patient-controlled analgesia (PCA). [1, 2] Further, it has been reported that lower doses of butorphanol may have ceiling effects. [3] Effective postoperative analgesia would not only improve patient satisfaction but also reduce the incidence of postoperative complications and shorten the duration of hospitalization. [4, 5] According to the available protocols for postoperative pain management, the ideal method is a combination of drugs. Previous studies have reported that use of an a 2 -adrenoceptor agonist can decrease the risk of cardiovascular side effects postoperatively. Dexmedetomidine is a highly selective a 2 adrenergic receptor agonist with sedative, analgesic, and antianxiety activity. [6, 7] However, data on the effects of different concentrations of dexmedetomidine are inadequate. The primary aim of this study was to evaluate the efficacy of dexmedetomidine in combination with sufentanil or butorphanol for postoperative analgesia in patients undergoing laparoscopic resection of a gastrointestinal tumor.
Methods

Study design and participants
Eighty patients (41 men, 39 women, aged 27-70 years) with American Society of Anesthesiologists physical status I to II and a Editor: Kazuo Hanaoka.
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The authors have no conflicts of interest. body mass index < 28 kg/m 2 undergoing laparoscopic resection of a gastrointestinal tumor were included. The study exclusion criteria included a history of cardiovascular disease, severe renal or hepatic insufficiency, bradycardia, atrioventricular block, chronic pain, and current use of analgesic medication. The patients were randomized into 4 groups of 20 patients each using a computer-generated randomization list to receive dexmedetomidine 1.5 mg/kgand sufentanil 2.0 mg/kg and ondansetron 0.4 mg/kg, diluted with 0.9% saline solution to 100 mL (group S 1 ); dexmedetomidine 2.0 mg/kg and sufentanil 2.0 mg/kg and ondansetron 0.4 mg/kg, diluted with 0.9% saline solution to 100 mL (group S 2 ); dexmedetomidine 1.5 mg/kg and butorphanol 0.15 mg/kg and ondansetron 0.4 mg/kg, diluted with 0.9% saline solution to 100 mL (group N 1 ); and dexmedetomidine 2.0 mg/kg and butorphanol 0.15 mg/kg and ondansetron 0.4 mg/kg, diluted with 0.9% saline solution to 100 mL (group N 2 ).
Anesthesia
The patients did not receive any medication before induction of anesthesia. At the start of anesthesia, peripheral venous access was established in the right upper extremity, and a 5-lead electrocardiogram, oxygen saturation (S p O 2 ), and blood pressure were monitored continuously. Anesthesia was induced by an intravenous infusion of dexmedetomidine 1.0 mg/kg (15 minutes before the start of surgery), etomidate 0.3 mg/kg, sufentanil 0.4 m g/kg, and cisatracurium 0.2 mg/kg. When the trachea was intubated, ventilation was mechanically controlled to maintain a tidal volume of 7 to 10 mL/kg, a respiratory rate of 12 breath/ min, and end-tidal carbon dioxide (P ET CO 2 ) at 35 to 45 mm Hg. Anesthesia was maintained by an intravenous infusion of propofol 4.0 to 8.0 mg/kg/min, remifentanil 4.0 to 8.0 mg/kg/ min, and cisatracurium 0.1 mg/kg/min. Hemodynamic stability was maintained intraoperatively. All patients received an intravenous injection of flurbiprofen axetil 50 mg and ondansetron 4 mg 15 minutes before completion of surgery. Propofol, remifentanil, and cisatracurium were then discontinued. All patients were offered an electronic infusion pump for intravenous PCA after surgery.
Outcome measures
Oxygen saturation, mean arterial pressure (MAP), heart rate (HR), visual analog score (VAS), and Ramsay sedation score (RSS) were recorded at enrollment (T 0 ), at extubation (T 1 ), and at 4 (T 2 ), 8 (T 3 ), 12 (T 4 ), 24 (T 5 ), and 48 (T 6 ) hours thereafter. Side effects and satisfaction scores were evaluated after surgery.
The VAS score was classified as no pain (score 0), mild pain (score 1-3), moderate pain (score 4-6), or severe pain (score 7-10). Sedation was assessed using the RSS (1, anxious; 2, cooperative and tranquil; 3, responding to command; 4, brisk response to stimulus; 5, sluggish response to stimulus; 6, no response to stimulus).
Ethics statement
The study protocol was approved by the local hospital ethics committee in Nanchang, China, and conducted from January 2014 to December 2015. Informed consent was obtained from all study participants.
Statistical analysis
Normally distributed data are expressed as the mean ± standard deviation. Between-group comparisons were performed using repeated-measures analysis of variance. Categorical variables were compared using the Chi-squared test, and intragroup comparisons were performed using the Wilcoxon rank-sum test. All P values < 0.05 were considered to be statistically significant. The statistical analysis was performed using Statistical Package for the Social Sciences version 17.0 software (SPSS Inc., Chicago, IL).
Results
The patient characteristics are summarized in Table 1 . There was no difference in patient sex, age, or weight, or duration of surgery between the study groups (P > 0.05). MAP increased in all groups at T 1 when compared with T 0 , but the difference was not statistically significant (Table 2) . HR decreased significantly in group S 2 at T 1 -T 5 when compared with the other groups (P < 0.05). MAP decreased significantly in group S 2 when compared with group S 1 at T 4 -T 6 (P < 0.05) and increased significantly in group N 1 when compared with group N 2 at T 4 -T 5 (P < 0.05). A statistically significant decrease in VAS was seen in group S 2 when compared with group S 1 at T 2 (P < 0.05) and with group N 2 at T 1 -T 2 (P < 0.05; Table 3 ). Two patients in group S 1 developed vomiting. There were no reports of drowsiness, respiratory depression, or other complications in any of the groups (Table 4 ). The patient satisfaction rate was higher in group S 2 (95%) than in the other groups (Table 5 ).
Discussion
Postoperative pain is a common patient complaint after surgery. Apfelbaum et al [8] reported that approximately 80% of their patients experienced pain after surgery and 86% had moderate to severe pain. Although postoperative pain is significantly less after laparoscopy than after open surgery, [9] the pain may still be considerable because of the transabdominal sutures and laparoscopic tacks used during the procedure. [2, 10] Medication patches and percutaneous pump devices have been used to decrease postoperative pain with limited success, so improving Values are expressed as the mean ± standard deviation or number (n) of patients.
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postoperative analgesia is an area of continued interest in laparoscopic surgery. The most common type of PCA involves use of an intravenous opioid because of its postoperative analgesic efficacy and prolonged duration of action. [11] However, this type of PCA has considerable side effects, including nausea, vomiting, motor block, urinary retention, and respiratory depression. [12, 13] Use of sufentanil has been investigated in some laparoscopic surgery studies. Damen et al [14] reported that intraoperative sufentanil was comparable with remifentanil in patients undergoing laparoscopic cholecystectomy. Early pain was decreased in patients receiving sufentanil, but at the Table 2 Comparison of hemodynamic changes in the treatment groups at the different time points. Values are expressed as the mean ± standard deviation. HR, = heart rate, MAP = mean arterial pressure, S p O 2 = oxygen saturation. * P < 0.05 for intragroup compared with T 0 time point. † P < 0.05 for groups S 2 and N 1 compared with group S 1 . ‡ P < 0.05 for groups S 2 and N 1 compared with group N 2 . Table 3 Comparison of visual analog score and Ramsay sedation score between the treatment groups at the different time points. 2.50 ± 0.69 2.05 ± 0.22 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 S 2 2.30 ± 0.47 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 N 1 2.50 ± 0.76 2.10 ± 0.66 2.05 ± 0.22 2.00 ± 0.37 2.00 ± 0.00 2.00 ± 0.00 N 2 2.55 ± 0.51 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00
Group
Values are expressed as the mean ± standard deviation. RSS, = Ramsay sedation score, VAS = visual analog score. * P < 0.05 for groups S 2 and N 1 compared with group S 1 . † P < 0.05 for groups S 2 and N 1 compared with group N 2 . Table 4 Side effects in the treatment groups.
Group n Nausea, n (%) Vomiting, n (%) Drowsiness Respiratory depression Table 5 Comparison of patient satisfaction levels between the treatment groups.
Group n Very satisfied, n (%) Satisfied, n (%) Moderately satisfied, n (%) Not satisfied, n (%) Satisfaction rate, % expense of opioid-related adverse effects. Butorphanol is a lipid-soluble narcotic agent with strong k-receptor agonist and weak m-receptor agonist/antagonist activity. The abovementioned narcotic analgesics have been used frequently for postoperative analgesia. [15] In recent years, there have been attempts to reduce the frequency of side effects associated with postoperative pain management by use of a combination of two or more drugs. [16] Recent studies have focused on nonopioid receptors with additional analgesic effects. Previous studies have demonstrated that dexmedetomidine, an a2-adrenoceptor agonist, causes dose-dependent hypotension, bradycardia, and sedation. Dexmedetomidine decreases the HR and blood pressure by decreasing plasma levels of norepinephrine and epinephrine. [17] Saadawy et al [18] reported a decrease in HR and MAP in their dexmedetomidine group within 25 to 35 minutes of caudal administration. In our study, we also found a decrease in HR and MAP, particularly in the group that received dexmedetomidine 2.0 mg/kg. Further, MAP decreased significantly in the group that received dexmedetomidine 2.0 mg/kg and sufentanil 2.0 mg/kg when compared with the other groups. Addition of dexmedetomidine 2.0 mg/kg to sufentanil or butorphanol in this study was not associated with an increased incidence of side effects. Our results are consistent with those of studies in patients undergoing laparoscopic bariatric surgery. In one early study, patients undergoing laparoscopic colorectal surgery who received intraoperative dexmedetomidine reported lower pain scores during the first 12 postoperative hours, and no opioid-sparing effect was found. [19] Dexmedetomidine also showed significant anxiolytic efficacy and durable analgesic efficacy, with a decreased need for postoperative opioid analgesia. Our study found that satisfactory patient sedation contributed to the lessening of postoperative pain. Our results indicated that patients were generally satisfied with their intravenous PCA system because the adjuvant combination of dexmedetomidine and sufentanil or butorphanol therein achieved an acceptable level of sedation.
In conclusion, our results show that the 2 doses of dexmedetomidine as an adjuvant to sufentanil and butorphanol can be safely used for postoperative analgesia in patients undergoing laparoscopic resection of a gastrointestinal tumor. The most effective dose of dexmedetomidine that did not lead to any complications was 2.0 mg/kg combined with sufentanil 2.0 mg/kg.
